Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Nabi Biopharmaceuticals has revealed results from a study which show its PhosLo drug provides good control of serum phosphorus, a key determinant of morbidity and mortality among end-stage renal disease patients.
Subscribe to our email newsletter
In the study, PhosLo was found to be more effective in controlling serum phosphorus than sevelamer, an established treatment for chronic renal failure marketed as Renagel by Genzyme Corporation. The results lend support to the use of PhosLo as a first line treatment for the indication.
The findings of the study were presented at the European Renal Association Congress in Glasgow, Scotland.
“We expect to further advance the body of clinical evidence supporting the use of PhosLo as a first-line therapy with the release of the results of the CARE-2 study later this year,” said Dr Henrik Rasmussen, senior vice president clinical, medical and regulatory affairs, Nabi Biopharmaceuticals.
The company has also received an updated timetable from European regulators related to the inspection of the PhosLo manufacturing facility, which is the last step required for approval for PhosLo in the EU. This inspection was anticipated to have been conducted in the second quarter of 2006, but is now expected to take place during the second half of 2006.